Latest Breaking News On - Clinical genitourinary cancer - Page 2 : vimarsana.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad . Myriad Genetics, Inc.February 12, 2021 GMT SALT LAKE CITY, Feb. 12, 2021 (GLOBE NEWSWIRE) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today additional data further validating the prognostic power of its Prolaris® test and its ability to help accurately predict which men with more aggressive prostate cancer will benefit from intensification of therapy and which patients may safely avoid such treatments. This second validation study was presented during an oral presentation at the American Society of Clinical Oncology Genitourinary Cancer Symposium (ASCO-GU) by Jonathan Tward M.D., Ph.D, associate professor in the Department of Radiation Oncology at the University of Utah.

United statesJared maxwellBracanalysis cdxScott gleasonToddd cohenPrometheus labs incUniversity of utahBank intlGenetics incExchange commissionAffairs for urology at myriad geneticsSupreme courtDepartment of radiation oncologyAmerican cancer societyAlice corpNational comprehensive cancer network